Plenty of things the company can talk about that w
Post# of 7805
(Total Views: 546)
Posted On: 12/14/2021 8:37:06 PM
Plenty of things the company can talk about that wouldn't interfere with a specific NDA
Prime example from Post 2100 11/18/2019
Sales and Marketing Updates
Following a highly productive week, we were able to complete packaging of the 15,000 unit purchase order to Mundipharma for their product launch in Singapore. Additionally, we have received a 7,000 unit purchase order from Mundipharma for shipment to the Philippines. We believe that MundiPharma, being a best-in-class company is committed to deploying their sales force and achieving the growth targets set forth in our sales agreements. We anticipate that orders for Mundipharma’s remaining South East Asia territories (Malaysia, Indonesia and Thailand) will be placed over the next 60 days.
Discussions are ongoing to finalize agreements with MundiPharma in the Middle East/North Africa region. Our renewal of the ISO certification and demonstrated ability to deliver product within a deadline has helped strengthen our position in these discussions. It is noteworthy that BioElectronics has received purchase orders from Mundipharma totaling 22,000 units within such a short period, and offers a glimpse into the strength and long-term growth potential of the Company when allied with a great sales channel partner.
Separately, we have a confirmed meeting date with our potential partner who is interested in the plantar fasciitis indication. Preliminary discussions thus far have progressed well and lead us to believe that a deal can be reached relatively quickly. Our meetings with other US companies looking to diversify their planogram offerings by adding non-drug alternatives like ActiPatch, have also progressed well.
Lastly, we have reached a new stage in discussions with two large corporations who have demonstrated an interest to distribute the product in South Africa and Russia, respectively. Both companies are market leaders in their countries with documented records of long-term success in the OTC space.
Prime example from Post 2100 11/18/2019
Sales and Marketing Updates
Following a highly productive week, we were able to complete packaging of the 15,000 unit purchase order to Mundipharma for their product launch in Singapore. Additionally, we have received a 7,000 unit purchase order from Mundipharma for shipment to the Philippines. We believe that MundiPharma, being a best-in-class company is committed to deploying their sales force and achieving the growth targets set forth in our sales agreements. We anticipate that orders for Mundipharma’s remaining South East Asia territories (Malaysia, Indonesia and Thailand) will be placed over the next 60 days.
Discussions are ongoing to finalize agreements with MundiPharma in the Middle East/North Africa region. Our renewal of the ISO certification and demonstrated ability to deliver product within a deadline has helped strengthen our position in these discussions. It is noteworthy that BioElectronics has received purchase orders from Mundipharma totaling 22,000 units within such a short period, and offers a glimpse into the strength and long-term growth potential of the Company when allied with a great sales channel partner.
Separately, we have a confirmed meeting date with our potential partner who is interested in the plantar fasciitis indication. Preliminary discussions thus far have progressed well and lead us to believe that a deal can be reached relatively quickly. Our meetings with other US companies looking to diversify their planogram offerings by adding non-drug alternatives like ActiPatch, have also progressed well.
Lastly, we have reached a new stage in discussions with two large corporations who have demonstrated an interest to distribute the product in South Africa and Russia, respectively. Both companies are market leaders in their countries with documented records of long-term success in the OTC space.
(3)
(0)BioElectronics Corporation (BIEL) Stock Research Links
Scroll down for more posts ▼